• Home
  • About Us
  • Team Members
  • News
  • Careers
    • Apply Now
  • Contact Us
NuShores BiosciencesNuShores Biosciences
  • Home
  • About Us
  • Team Members
  • News
  • Careers
    • Apply Now
  • Contact Us
NuShores Biosciences LLC awarded NIH SBIR Fast Track funding

NuShores Biosciences LLC awarded NIH SBIR Fast Track funding

August 8, 2018

Stony Brook University’s School of Dental Medicine is research collaboration partner

Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that it has received a 2.5-year SBIR Fast Track grant for $1.7 million. The research grant is to study NuShores’ NuCressTM bone filler scaffolds in craniofacial tissues. The National Institute of Dental and Craniofacial Research (NIDCR), a component of the National Institutes of Health (NIH), provided the research funding. NuShores has partnered in this study with Stony Brook University (SBU) School of Dental Medicine; a cross-disciplinary team of experts in oral and maxillofacial surgery and periodontology, in preclinical models and clinical trials. Alex Biris, NuShores’ Co-founder and Chief Technical Officer, responded “This is a significant win to further validate NuShores’ technology and has been made possible through our university relationships, Arkansas’ small business development infrastructure, and tireless work by a dedicated team. We are grateful.”This research addresses the limitations of current bone grafting techniques for dental implants: difficulties with fixation and stabilization, insufficient bone regeneration, high morbidity using autogenous block grafts, prolonged healing of up to 9 months, and high costs. Although pre-implant reconstructive surgeries are commonly performed, an estimated 7% of patients are unable to receive dental implants due to these limitations. NuShores will be investigating the advantages of NuCressTM bone filler scaffold technology as a revolutionary advancement in bone healing and a transformational technology for dentists, periodontists and oral surgeons for tooth salvage treatments at a fraction of the cost and healing times required for today’s technologies. Such preclinical studies are essential before approval for use in humans. “I have seen the composite xenograft / alloplast to be used in the proposed project and feel strongly that the outcome . . . will lead to important clinical trials on its use to enhance implant therapy,” says Vincent J. Iacono, DMD, Tarrson Family Professor of Periodontology, SUNY Distinguished Service Professor and Chair, School of Dental Medicine, Stony Brook University.

About NuShores Biosciences LLC
NuShores’ vision is to improve the quality of life for people globally and to compete successfully in the bone-substitute materials industry. Early studies suggest that NuShores’ licensed, patented
technology could deliver improved solutions for bone regeneration while cutting healthcare costs, lowering treatment risks and reducing healing times. NuShores’ NuCressTM scaffold offers a number of benefits to date not achieved by currently marketed bone regeneration products, therefore promising to bring better treatment outcomes to millions of people with severe bone injuries. NuShores has the exclusive, global license from University of Arkansas Little Rock to commercialize university owned patented and patent-pending technologies. Drs. Alexandru Biris and David Anderson along with two other Little Rock investors founded NuShores in 2014. Dr. Biris is Director of the UA Little Rock Center of Integrative Nanotechnology Sciences (CINS) and Faculty in UA Little Rock’s College of Engineering.  Dr. David Anderson, founder, is a long-time collaborator with Dr. Biris and UA Little Rock. Dr. Anderson is the Head of the Department of Large Animal Clinical Sciences at University of Tennessee Knoxville’s Center for Veterinary Medicine (UTCVM) and a specialist in surgery.

About Stony Brook University School of Dental Medicine
Stony Brook University’s (SBU) cross-disciplinary team of experts in oral and maxillofacial surgery and periodontology, in preclinical models and clinical trials, will evaluate NuCressTM scaffolds in craniofacial tissues. SBU School of Dental Medicine is among the elite NIH/NIDCR-funded research-intensive dental schools in the nation. They are an integrated part of a broader research community at SBU with extensive research collaborations with the School of Medicine, College of Engineering and Applied Sciences, and Program in Public Health. David K. Lam, MD, DDS, PhD, FRCDC, Chair, Department of Oral and Maxillofacial Surgery, will serve as SBU’s Project Director for the NuShores SBIR Fast Track effort. Dr. Lam is a surgeon-scientist with extensive experience in preclinical animal model testing and novel model development, clinical trials, and surgical innovations. Dr. Srinivas Myneni, BDS, MS, PhD, Director of Periodontal Research in the Department of Periodontology, will serve as Co-Investigator. Dr. Myneni is an expert in periodontology and implant dentistry, with extensive experience in pre-clinical and clinical research in tissue regeneration, management of extraction sockets, implant placement, ridge preservation, and periodontal and bone regeneration. For more information, visit https://dentistry.stonybrookmedicine.edu

About the SBIR Program
The SBIR Program (Small Business Innovation Research) involves eleven (11) federal agencies investing over $3 billion a year in high risk / high payoff research and development conducted by the nation’s leading science-technology innovators such as NuShores Biosciences LLC. NuShores’ award is known as a Fast Track Grant where funding occurs when SBIR Phase I and Phase II proposals are peer reviewed at the same time, and then granted in a single award. This approach expedites funding and research for the companies. Research described in this press release is supported by the National Center for Dental and Craniofacial Research of the National Institutes of Health under award number 1R44DE028213-01.

 

Contact
To learn more about this announcement, please contact
Sharon C. Ballard, CEO
NuShores Biosciences LLC
sharon@nushores.com

Share

They’ve Said About US

  • The opportunity to serve on the board of NuShores is exciting and thought-provoking.  As an active member of the scientific community with a specific interest in orthopedics, the ongoing research is especially relevant and exciting for me.  I am delighted to have to opportunity to help such a robust and creative group move their technology and research efforts forward

    Larry Suva PhD
    Professor and Department Head Texas A&M University
  • I am delighted to be working with such a wonderful team on lifechanging technologies and applications.  It is an honor to be along for the journey.

    James G. Wetrich
    Fellow of the American College of Healthcare Executives
  • It is a rare opportunity to be able to support the historic scientific discoveries licensed to NuShores from UA Little Rock that will have a significant positive impact on public health and clinical practices.  I am blessed to be able to participate with NuShores team in maturing such scientific breakthroughs to commercial success

    Andrew G. Kumpuris
    Founder and Advisor
  • The NuShores group has assembled a very strong development team under Dr. Biris and the operational depth needed to bring their novel materials to the market.  I am very excited to be contributing to NuShores and Alex’ team.

    Mike Douglas PhD
    Executive Director Texas Life Science Collaboration Center
  • I am honored to serve on the advisory board for NuShores Biosciences LLC. I look forward to opportunities to contribute to your efforts with my experience and lessons learned in the areas of science – technology planning and commercialization, and to assist in the clinical aspects to make it available to patients as soon as possible.

    C. Lowry Barnes MD
    Professor and The Carl L. Nelson, M.D. Distinguished Chair in Orthopaedic Surgery at UAMS
  • I am very excited to work with the team at NuShores in the development of an enabling technology in tissue regeneration.  I have worked with the group for some time now and have the greatest respect for their approach to the challenge and the quality of their research.  I believe that the rigor behind their work is world class and will be regarded as a new standard of care in repairing bone loss.

    Jeff Skiba PhD
    Founder of Vomaris Innovations Inc.
  • I am pleased to serve on the NuShores’ Advisory Board and look forward to contributing to their venture’s product successes.  There is a need for their innovative NuCress™ bone void filler that has potential use in my areas of medical practice.  I look forward to working with the NuShores team in accomplishing the scientific, regulatory and development milestones to make such a product available to physicians and their patients

    James Y. Suen MD
    Professor and Chairman of the Department of Otolaryngology – Head and Neck Surgery at University of Arkansas Medical Sciences

Contact Us

Send us a message at your convenience

Send Message

Search

Follow Us

  • LinkedIn

READ OUR FCOI

Contact Info

  • NuShores Biosciences LLC
  • 1523 South Bowman St. Suite 3-H, Little Rock, Arkansas 72211
  • 866-NUCRESS
  • info@nushores.com
  • nushores.com

In the News

  • NuShores receives additional funding for biomedical manufacturing automation to by US Army
  • NuShores Biosciences receives commercialization program funding for NuCress™ bone filler scaffolds
  • NuShores welcomes a new Quality and Regulatory medical device professional to Little Rock

Awards


© 2026 —NuShores Biosciences LLC

Prev Next